Introduction ▼
There has been intense discussion of possible systematic diff erences in therapeutic responses to antidepressants between patients diagnosed with unipolar major depressive disorder (UP-MDD) vs. the several types of bipolar disorder (BPD). In general, there appears to be a broad clinical impression that acutely depressed BPD patients respond to antidepressant treatment less favorably than those with UP-MDD, have a higher risk of mood-switching, or are diffi cult to study owing to the clinical and therapeutic complexity in BPD [1 -4] . BP depression is often complicated by the presence of complex and shifting mixtures of depressive, dysphoric-agitated, hypomanic, or psychotic features, as well as common co-morbidity with anxiety and substanceuse disorders [5] . This clinical complexity, common instability over time, as well as risk of
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Methods

▼ Search strategy and study selection
We performed a comprehensive literature search for reports of therapeutic trials of antidepressant treatments for depression that included both UP and BP major aff ective disorder patients with acute major depression, through May 2010, using searches of MEDLINE / PubMed (from 1955 [19] ), EMBASE (from 1988 [20] ) and LILACS (from 1982 [21] ), as well as the Internet search engines, PsiTri [22] and Google-Scholar [23] . Search terms included various combinations of " antidepressant " , " bipolar depression " , " bipolar disorder " , " controlled trial " , " depression " , " effi cacy " , " major depression " , " major depressive disorder " , " randomized controlled trial " , " treatment " , and " unipolar disorder " . We also considered reports cited in identifi ed studies and in recent reviews. A priori inclusion criteria broadly considered peer-reviewed, prospective or retrospective, randomized or non-randomized, blinded or open-label clinical trials involving treatment with any clinically employed antidepressant (with or without other psychotropic medicines or a placebo) and compared rates of response, remission, or improvement in episodes of acute depression between patients diagnosed with UP-MDD vs. BPDs based on standardized international diagnostic criteria (DSM-IV or ICD-10, which are very similar in criteria for major depressive episodes [24] ); we also sought information on selection criteria, sex distribution, mean age, type and dose of antidepressant, and duration of treatment. Data from potential studies were extracted independently by the authors, and any discrepancies were resolved by consensus. The primary comparison was antidepressant response vs. diagnosis. In addition to data extracted from published reports, we also included original data from a collaborating Sardinian mood disorder center [25, 26] for type I and type II BPD patients, based on previously characterized diagnostic and assessment methods [27] . These prospectively collected data involved clinical treatments with a range of antidepressants, with or without other psychotropic drugs, based on diagnoses of BPD types I or II, or recurrent UP-MDD, and comparisons of men and women in each diagnostic category. Data were subjected to random-eff ects meta-analysis and metaregression modeling, using Stata-8.0 ® statistical software (StataCorp, College Station, TX), based on reported or estimated ratios of responders to non-responders with antidepressant treatment as the primary outcome for meta-analyses [28, 29] . For studies that reported outcomes as continuous measures of improvements in standard depression symptom severity rating scale scores, we converted % improvement in depression ratings to % responding as a comparable estimate for both UP and BP disorder patients, since the 2 measures are often remarkably similar, and the results are comparable between diagnostic groups [30] . 
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Baseline illness severity was adequately matched between UP and BP cases; diagnoses were based on DSM criteria in 8, and ICD criteria in 2 studies [34, 35] ; study designs were prospective Table 1 ] ). Rates of mood-switching ( % / week) were similar among BP-I (2.28) and BP-II patients (2.97), but approximately 97 % involved hypomania in BP-II patients, and 41 % mania + 59 % hypomania in BP-I cases in studies reporting that information [25, 26] . Moreover this risk, as expected, was more than 9-times higher among all BP (2.50 % / week) than UP depressed patients (0.275 % / week, almost all as hypomania [25, 26] ). This low observed switch-risk among UP-MDD patients suggests that misdiagnosis of apparent UP-MDD was uncommon.
Discussion ▼
The present fi ndings underscore 2 important conclusions. First, the number and quality of studies pertaining to direct comparisons of antidepressant responses among acutely depressed UP-MDD vs. BPD patients are strikingly limited. This circumstance is surprising for such a fundamental question that has remained unanswered since introduction of the concept of BPD as a separate subtype of manic-depressive illnesses in the mid-20 th century, and of modern antidepressants in the 1950s [5, 39] . Second, the studies that we did fi nd were limited in number, with variable methodological rigor and independence of subjects sampled, and they provided no basis for support of major diff erences in antidepressant responses between UP-MDD and BPD patients. This conclusion -though tentative due to the limitations of the available data -is consistent with recent proposals that antidepressant treatment may or may not be as eff ective in BP depression as in UP-MDD, may be superior with modern antidepressants compared to tricyclics, needs to be employed cautiously and is potentially risky in acute BP-depression, not only due to risk of inducing mania ( • ▶ Table 1 ), but possibly destabilizing the longterm course and leading to treatment-resistance [1 -3, 40 -47] , as well as having uncertain but possibly quite limited long-term benefi t, particularly in comparison with mood-stabilizers [3, 13, 40, 45] . Despite much discussion, and with limited directly relevant data, there remains uncertainty to what extent the evidently widespread impression that depressed BPD patients may respond less well to antidepressants than UP-MDD patients pertains to effi cacy per se , or to concerns about potential mooddestabilizing eff ects, with or without simultaneous treatment with mood stabilizers, whose protective eff ects with antidepressant treatment also remain uncertain [6] . It is also important to emphasize that the reported fi ndings may be confounded by limited control over treatments in most of the studies identifi ed, and by their sometimes retrospective designs, with the likelihood that clinical treatment was individualized and adjusted to tolerability so as to favor positive clinical outcomes in some studies. Such uncontrolled variance may well contribute to data that are highly regressed to average outcomes, tending toward a conclusion of " no diff erence " that may well not represent defi nitive evidence of similarity of response (type II error). Even such potential limitations leave the possibility that clinical use of antidepressants may be benefi cial for some BPD patients; surely it is highly prevalent [48, 49] . In general, possible clinical dissimilarities between " depressive " syndromes in UP-MDD vs. BP-I and perhaps BP-II disorders discussed above, as well as marked dissimilarities in their clinical treatment and their risks of antidepressant-associated mania or hypomania Table 1 ) or destabilization over time [1] , may well make comparisons -especially of simple, controlled antidepressant trials without mood-stabilizers -unusually challenging [12, 40] . On the other hand, similar responses to antidepressant treatment among UP-MDD and BP-II patients were found in a randomized, controlled trial [32] , as well as in several others that may involve somewhat individualized clinical treatments ( • ▶ Table 1 ), underscoring the possibility that these two mood syndromes may be quite similar and distinct from BP-I disorder [50] .
In conclusion, given the continued importance of the question of possible diagnostic diff erences in responses to antidepressant drugs, and in view of the major limitations of available research studies and fi ndings involving direct comparisons of BPD and UP-MDD patients, it seems clear that additional, prospective, controlled trials are needed. Ideally, these would include BP and UP disorder patients who are properly matched by demographic and clinical characteristics, and with greater control over the types, doses, and exposure-times for antidepressants and over other treatments provided as well as consideration of rates of adverse eff ects on mood per exposure time, as well as simple antidepressant effi cacy.
